LV11992B - METALPIROLIDINYL METHYL ALLEGAL SALT - Google Patents

METALPIROLIDINYL METHYL ALLEGAL SALT Download PDF

Info

Publication number
LV11992B
LV11992B LVP-97-256A LV970256A LV11992B LV 11992 B LV11992 B LV 11992B LV 970256 A LV970256 A LV 970256A LV 11992 B LV11992 B LV 11992B
Authority
LV
Latvia
Prior art keywords
salt
fumarate
compound
fumarate salt
ylmethyl
Prior art date
Application number
LVP-97-256A
Other languages
English (en)
Latvian (lv)
Other versions
LV11992A (lv
Inventor
Martin James Wythes
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of LV11992A publication Critical patent/LV11992A/xx
Publication of LV11992B publication Critical patent/LV11992B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LVP-97-256A 1995-05-20 1997-12-11 METALPIROLIDINYL METHYL ALLEGAL SALT LV11992B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510223.2A GB9510223D0 (en) 1995-05-20 1995-05-20 Therapeutic agent
PCT/EP1996/001560 WO1996036632A1 (en) 1995-05-20 1996-04-10 Pyrrolidinyl methyl indole salt

Publications (2)

Publication Number Publication Date
LV11992A LV11992A (lv) 1998-03-20
LV11992B true LV11992B (en) 1998-06-20

Family

ID=10774766

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-256A LV11992B (en) 1995-05-20 1997-12-11 METALPIROLIDINYL METHYL ALLEGAL SALT

Country Status (42)

Country Link
US (1) US5994387A (no)
EP (1) EP0827503B1 (no)
JP (1) JP3233940B2 (no)
KR (1) KR100295255B1 (no)
CN (1) CN1063175C (no)
AP (1) AP738A (no)
AR (1) AR003949A1 (no)
AT (1) ATE194986T1 (no)
AU (1) AU701154B2 (no)
BG (1) BG63046B1 (no)
BR (1) BR9610858A (no)
CA (1) CA2219631C (no)
CO (1) CO5040221A1 (no)
CZ (1) CZ287939B6 (no)
DE (1) DE69609504T2 (no)
DK (1) DK0827503T3 (no)
DZ (1) DZ2034A1 (no)
ES (1) ES2148753T3 (no)
GB (1) GB9510223D0 (no)
GR (1) GR3034290T3 (no)
HK (1) HK1017884A1 (no)
HR (1) HRP960223B1 (no)
HU (1) HU217657B (no)
IL (1) IL118239A (no)
IS (1) IS1908B (no)
LV (1) LV11992B (no)
MA (1) MA23876A1 (no)
MX (1) MX9708966A (no)
MY (1) MY132066A (no)
NO (1) NO312068B1 (no)
NZ (1) NZ306448A (no)
OA (1) OA10747A (no)
PL (1) PL183142B1 (no)
PT (1) PT827503E (no)
RU (1) RU2161618C2 (no)
SK (1) SK281782B6 (no)
TN (1) TNSN96074A1 (no)
TR (1) TR199701397T1 (no)
UA (1) UA44320C2 (no)
WO (1) WO1996036632A1 (no)
YU (1) YU29496A (no)
ZA (1) ZA963938B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906406C1 (no) * 1989-03-01 1990-10-25 Goedecke Ag, 1000 Berlin, De
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
AU651637B2 (en) * 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.

Also Published As

Publication number Publication date
CZ364897A3 (cs) 1998-11-11
MA23876A1 (fr) 1996-12-31
HRP960223B1 (en) 2000-12-31
AU701154B2 (en) 1999-01-21
ES2148753T3 (es) 2000-10-16
DK0827503T3 (da) 2000-11-20
KR100295255B1 (ko) 2001-08-07
AU5500596A (en) 1996-11-29
TR199701397T1 (xx) 1998-03-21
HUP9801761A2 (hu) 1999-05-28
JPH10506639A (ja) 1998-06-30
PL183142B1 (pl) 2002-05-31
CZ287939B6 (cs) 2001-03-14
PL323143A1 (en) 1998-03-16
CA2219631A1 (en) 1996-11-21
IS1908B (is) 2003-12-31
GR3034290T3 (en) 2000-12-29
UA44320C2 (uk) 2002-02-15
OA10747A (en) 2002-12-11
HK1017884A1 (en) 1999-12-03
RU2161618C2 (ru) 2001-01-10
US5994387A (en) 1999-11-30
WO1996036632A1 (en) 1996-11-21
EP0827503B1 (en) 2000-07-26
CN1185152A (zh) 1998-06-17
CO5040221A1 (es) 2001-05-29
NO312068B1 (no) 2002-03-11
ZA963938B (en) 1997-11-17
IL118239A0 (en) 1996-09-12
ATE194986T1 (de) 2000-08-15
JP3233940B2 (ja) 2001-12-04
BR9610858A (pt) 1999-07-13
BG63046B1 (bg) 2001-02-28
KR19990014934A (ko) 1999-02-25
HRP960223A2 (en) 1997-10-31
NO975210D0 (no) 1997-11-13
YU29496A (sh) 1998-12-23
TNSN96074A1 (fr) 2005-03-15
IS4605A (is) 1997-10-30
AR003949A1 (es) 1998-09-30
DE69609504D1 (de) 2000-08-31
SK281782B6 (sk) 2001-07-10
IL118239A (en) 2000-10-31
AP9600801A0 (en) 1996-04-30
MY132066A (en) 2007-09-28
EP0827503A1 (en) 1998-03-11
GB9510223D0 (en) 1995-07-19
BG102053A (en) 1998-06-30
NZ306448A (en) 1998-10-28
HUP9801761A3 (en) 1999-06-28
HU217657B (hu) 2000-03-28
SK154197A3 (en) 1999-01-11
CA2219631C (en) 2001-01-23
DE69609504T2 (de) 2000-12-14
CN1063175C (zh) 2001-03-14
MX9708966A (es) 1998-03-31
PT827503E (pt) 2000-11-30
LV11992A (lv) 1998-03-20
AP738A (en) 1999-03-23
NO975210L (no) 1997-11-13
DZ2034A1 (fr) 2002-07-21

Similar Documents

Publication Publication Date Title
NO308999B1 (no) Nye, kjemiske forbindelser, og farmasøytisk preparat inneholdende disse
CS228119B2 (en) Production of n2-arylsulphonyl-l-argininamides
ZA200402999B (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
CA3066601C (en) Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of derivative thereof and method for preparing same
EP4073036B1 (en) Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
LV11992B (en) METALPIROLIDINYL METHYL ALLEGAL SALT
JPH07507782A (ja) ５−（１，２，４−トリアゾール−１−イルメチル）−３ｈ−イソベンゾフラン−１−オン誘導体，それらの製造およびアロマターゼ阻害剤としての使用
AU657591B2 (en) Stable salts of (+)-(1S,2R)-2-((N-(2-hydroxylamino-2-oxoethyl)-N-methyl- amino)carbonyl)cyclohexane-1-carboxylic acid, process for their preparation and pharmaceutical compositions containing them
EA001363B1 (ru) Кристаллический фармацевтический продукт
US10329264B2 (en) Process for the preparation of isocarboxazid
KR102209701B1 (ko) 토파시티닙의 신규한 결정형 형태 및 이의 제조방법
US20230382897A1 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
JP3062249B2 (ja) ドーパミン再取込み阻害剤
WO2008092816A2 (en) Novel polymorphic forms of n-piperidino-5-(4-chlorophenyl)-1(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
CA2235396A1 (en) Salts of n-(4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)benzamide
WO2005023790A1 (en) (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid sodium salt